172
Participants
Start Date
April 10, 2018
Primary Completion Date
June 3, 2019
Study Completion Date
October 3, 2020
Prexasertib
Administered IV
Institut Jules Bordet, Brussels
Prince of Wales Hospital, Randwick
Concord Repatriation General Hospital, Concord
Westmead Hospital, Wentworthville
GZA St Augustinus, Wilrijk
Peter MacCallum Cancer Centre, Melbourne
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg, Leuven
Royal Brisbane and Womens Hospital, Herston
Mater Adult Hospital Brisbane, South Brisbane
Flinders Medical Centre, Bedford Park
Burnside War Memorial Hospital, Toorak Gardens
Hospital Reina Sofia, Córdoba
Thomas Jefferson University, Philadelphia
Istituto Europeo di Oncologia, Milan
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Sarah Cannon Research Institute SCRI, Nashville
Tennessee Oncology PLLC, Nashville
University of Tennessee Medical Center, Knoxville
Sioux Valley Clinic, Sioux Falls
Research Medical Center, Kansas City
Cancer Care Associates, Tulsa
Istituto Tumori Fondazione G. Pascale IRCCS, Napoli
Arizona Oncology Associates, P.C., Tucson
Kaiser Permanente Medical Center, Vallejo
Seattle Cancer Care Alliance, Seattle
Rambam Medical Center, Haifa
Sheba Medical Center, Ramat Gan
Shaare Zedek Medical Center, Jerusalem
University of Southern Florida School of Medicine, Gainesville
Dana Farber Cancer Institute, Boston
Dartmouth Hitchcock Medical Center, Lebanon
Rhode Island Hospital, Providence
Policlinico Univ. Agostino Gemelli, Rome
Samsung Medical Center, Seoul
Seoul National University Hospital, Seoul
Asan Medical Center, Seoul
Severance Hospital Yonsei University Health System, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
University College Hospital - London, London
Christie NHS Foundation Trust, Manchester
Mount Vernon Hospital, Northwood
Royal Surrey County Hospital, Guildford
Royal Marsden Hospital, Sutton
Northampton General Hospital, Northampton
Eli Lilly and Company
INDUSTRY